Remedy of human coroviruse infection with genetic nanocomposit drug

Phase 1

• Conditions: Infectious disease and respiratory of the Corona virus.; Coronavirus infection; B34.2

• Registration Number: IRCT20200321046828N1
• Lead Sponsor: RNA biotechnology, Science base company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Infection with coronavirus

Exclusion Criteria

People with multiple problems
Cancer
Critical physical condition

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.

Secondary Outcome Measures

Name	Time	Method
General condition of people and vitality after treatment. Timepoint: After 8-12 days after the start of treatment. Method of measurement: Examination and explanation.